Page 131 - Educacional Ponenecias Congreso SEHH-STH 2020

5. Wang H, Wang C, Zhao MH, Chen M. Neutrophil extracellular traps can activate alternative complement pathways. Clin Exp Immunol. 2015;181:518-27.
6. Gloude NJ,Khandelwal P,Luebbering N,Lounder DT,Jodele S,Alder MN,et al. Circulating dsDNA, endothelial injury, and complement activation in throm- botic microangiopathy and GVHD. Blood. 2017;130:1259-66.
7. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124:645-53.
8. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and mar- row transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571-5.
9. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JM, Gratwohl A, et al. Diag- nostic criteria for hematopoietic stem cell transplant-associated microangi- opathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95-100.
10. Cho BS, Yahng SA, Lee SE, Eom KS, Kim YJ, Lee S, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation.Transplantation. 2010;90:918-26.
11. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, et al. A new paradigm: Diagnosis and management of HSCT-associated throm- botic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29:191-204.
12. George JN, Selby GB. Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant. 2004;33:1073-4.
13. Carmona A, Díaz-Ricart M, Palomo M, Molina P, Pino M, Rovira M, et al. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus- sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Mar- row Transplant. 2013;19:1439-45.
14. UderzoC,BonanomiS,BuscaA,RenoldiM,FerrariP,IacobelliM,etal.Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.Transplantation. 2006;82:638-44.
15. JodeleS,FukudaT,VinksA,MizunoK,LaskinBL,GoebelJ,etal.Eculizumab therapy in children with severe hematopoietic stem cell transplantation- associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20:518-25.
16. Carreras E, Díaz-Ricart M. Early Complications of Endothelial Origin. En: Car- reras E, Dufour C, Mohty M, Kröger N (eds.). The EBMT Handbook: Hemato- poietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Cham (CH): Springer; 2019. Chapter 42.
17. Poullin P, Delmotte N, Sanderson F, Roche M, Gensollen S. Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced sol- vent/detergent fresh frozen plasma for the treatment of thrombotic microan-
giopathy: the first French experience in a single center. Transfus Apher Sci.
2020;59:102587.
18. Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in
blood and marrow transplantation. Blood Adv. 2018;2:1495-509.
19. Uderzo CC, Jodele S, Missiry ME, Ciceri F, Busca A, Bacigalupo A, et al. Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Consen- sus Based Diagnostic and Therapeutic Recommendations: Which TA-TMA
Patients to Treat and When? J Bone Marrow Res. 2014;2:1000152.
20. Yeates L, Slatter MA, Bonanomi S, Lim FLWI, Ong SY, Dalissier A, et al. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a ret- rospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation. Bone Marrow
Transplant. 2017;52:762-4.
21. Devadas SK, Toshniwal M, Bagal B, Khattry N. Successful Treatment of Trans-
plant Associated Thrombotic Microangiopathy (TA-TMA) with Low Dose Defib-
rotide. Indian J Hematol Blood Transfus. 2018;34:469-73.
22. Marr H, McDonald EJ, Merriman E, Smith M, Mangos H, Stoddart C, et al. Suc- cessful treatment of transplant-associated microangiopathy with rituximab.
N Z Med J. 2009;122:72-4.
23. Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B, et al. Replace-
ment of calcineurin inhibitors with daclizumab in patients with transplanta- tion-associated microangiopathy or renal insufficiency associated with graft- versus-host disease. Bone Marrow Transplant. 2006;38:445-51.
24. Dhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in Transplant-Associated Thrombotic Microangiopathy. Clin Appl Thromb Hemost. 2017;23:175-80.
25. Jodele S, Dandoy CE, Lane A, Laskin BL,Teusink-Cross A, Myers KC, et al. Com- plement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135:1049-57.
26. Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Mar- tínez-Sánchez J. Complement Activation and Thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2019;14:1719-32.
❯ Agradecimientos
Este trabajo ha sido posible gracias a las ayudas re- cibidas por parte de la Deutsch José Carreras Leukä- mie Stiftung (grant 11R/2016 and 03R/2019) y de Jazz Pharmaceuticals (IST-16-10355).
❯ Conflictos de interés
EC forma parte del grupo de ponentes de Jazz Phar- maceutical plc.
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
131